Cisplatin-associated anemia: an erythropoietin deficiency syndrome
- PMID: 7706473
- PMCID: PMC295669
- DOI: 10.1172/JCI117840
Cisplatin-associated anemia: an erythropoietin deficiency syndrome
Abstract
Cisplatin-based therapy results in a cumulative anemia that is disproportionate to the effects on other blood cells. The severity of this treatment-induced anemia and the resultant transfusion requirement in cancer patients correlate with cisplatin-induced renal tubular dysfunction. Observed/expected serum erythropoietin (EPO) ratios decline with progressive cisplatin therapy and are proportionate to the degree of renal dysfunction. Recovery from anemia and of observed/expected serum EPO ratios in patients occurs after cessation of cisplatin therapy, along with restoration of renal tubular function. Creatinine clearance, however, remains permanently depressed. Cisplatin-treated rats develop progressive renal dysfunction and anemia that persists for many weeks, without effects on white blood cell counts. The anemia is also associated with a lack of expected EPO and reticulocyte response. With EPO administration, cisplatin-treated rats exhibit a greater reticulocyte response and hematocrit increment then non-cisplatin-treated rats given EPO, indicating minimal erythroid precursor cell damage from cisplatin. These results indicate the primary etiology of cisplatin-associated anemia is a transient, but persisting EPO deficiency state resulting from cisplatin-induced renal tubular damage, which can be prevented or treated by hormone (EPO) replacement.
Similar articles
-
Effects of cisplatin on erythropoietin production in rats.J Toxicol Sci. 1996 Aug;21(3):157-65. doi: 10.2131/jts.21.3_157. J Toxicol Sci. 1996. PMID: 8887884
-
Cadmium and cisplatin damage erythropoietin-producing proximal renal tubular cells.Arch Toxicol. 2006 Oct;80(10):680-6. doi: 10.1007/s00204-006-0093-1. Epub 2006 Mar 23. Arch Toxicol. 2006. PMID: 16555044
-
Erythropoietin ameliorates anemia of cisplatin induced acute renal failure.ASAIO J. 1998 Jan-Feb;44(1):44-7. doi: 10.1097/00002480-199801000-00010. ASAIO J. 1998. PMID: 9466500
-
[Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].Med Pregl. 2001 May-Jun;54(5-6):235-40. Med Pregl. 2001. PMID: 11759218 Review. Croatian.
-
Interrelationship between erythropoietin and erythropoiesis: insights from renal transplantation.Am J Kidney Dis. 1991 Oct;18(4 Suppl 1):54-6. Am J Kidney Dis. 1991. PMID: 1928080 Review.
Cited by
-
Erythropoietin response is inadequate in cancer patients receiving chemotherapy.Int J Hematol. 2001 Dec;74(4):416-20. doi: 10.1007/BF02982085. Int J Hematol. 2001. PMID: 11794697
-
Hesperidin ameliorates cisplatin induced hepatotoxicity and attenuates oxidative damage, cell apoptosis, and inflammation in rats.Saudi J Biol Sci. 2022 May;29(5):3157-3166. doi: 10.1016/j.sjbs.2022.01.052. Epub 2022 Jan 29. Saudi J Biol Sci. 2022. PMID: 35844386 Free PMC article.
-
Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival.Biol Res. 2025 Jan 18;58(1):4. doi: 10.1186/s40659-024-00581-3. Biol Res. 2025. PMID: 39827154 Free PMC article.
-
Genetic polymorphisms and platinum-induced hematological toxicity: a systematic review.Front Pharmacol. 2024 Aug 21;15:1445328. doi: 10.3389/fphar.2024.1445328. eCollection 2024. Front Pharmacol. 2024. PMID: 39234108 Free PMC article.
-
Nano Ellagic Acid Counteracts Cisplatin-Induced Upregulation in OAT1 and OAT3: A Possible Nephroprotection Mechanism.Molecules. 2020 Jul 2;25(13):3031. doi: 10.3390/molecules25133031. Molecules. 2020. PMID: 32630784 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials